Sugi Predict

Sugi Predict / Compounds / SCHEMBL1120340

SCHEMBL1120340

SCHEMBL1120340

O=C1C=C2C(=Nc3ccccc32)C(=O)N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.43
▸ LMNA P02545 3/20 0.43
▸ GAA P10253 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ APAF1 O14727 1/20 0.38
▸ HSP90AA1 P07900 1/20 0.38
▸ HSP90AB1 P08238 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ HK1 P19367 1/20 0.38
▸ GALK1 P51570 1/20 0.38
▸ HKDC1 Q2TB90 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ SRC P12931 2/20 0.38
▸ CTRB1 P17538 2/20 0.38
▸ CCNE1 P24864 2/20 0.38
▸ CDK2 P24941 2/20 0.38
▸ AHR P35869 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30516787 1.00 MAPT (0.43) MAPTLMNAGAAALDH1A1KMT2A
SCHEMBL121405 0.73 GSK3B (0.50) MAPTLMNAALDH1A1KMT2AMEN1
SCHEMBL27664385 0.73 GSK3B (0.50) MAPTLMNAALDH1A1KMT2AMEN1
SCHEMBL11120799 0.71 GSK3B (0.48) MAPTLMNAALDH1A1KMT2AMEN1
SCHEMBL7007833 0.69 MAPT (0.38) MAPTLMNAGAAALDH1A1KMT2A
SCHEMBL30019213 0.68 ABCG2 (0.62) MAPTLMNAGAAALDH1A1KMT2A
SCHEMBL261676 0.68 ABCG2 (0.62) MAPTLMNAGAAALDH1A1KMT2A
SCHEMBL16742423 0.68 ALDH1A1 (0.36) MAPTLMNAALDH1A1KMT2AMEN1
Hydrochloric Acid SCHEMBL7004542 0.68 MAPT (0.37) MAPTLMNAGAAALDH1A1KMT2A
Hydrochloric Acid SCHEMBL7004514 0.68 MAPT (0.37) MAPTLMNAGAAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0859778-B1 TETRAHYDROIMIDAZOPYRIDOINDOLEDIONES AS INHIBITORS OF cGMP SPECIFIC PDE ICOS CORP (US) 2001-12-19 — — EP claimed
EP-0859778-A2 CHEMICAL COMPOUNDS ICOS CORPORATION (US) 1998-08-26 — — EP claimed
WO-1996032003-A2 TETRAHYDROIMIDAZOPYRIDOINDOLEDIONES AND THEIR USE AS MEDICAMENTS ICOS CORPORATION (US) 1996-10-17 — — WO claimed
US-20180162859-A1 TETRACYCLIC AUTOTAXIN INHIBITORS ATXCO, INC. 2018-06-14 — — US disclosed
US-20180118804-A1 GROWTH FACTOR ANTAGONISTS FOR ORGAN TRANSPLANT ALLOIMMUNITY AND ARTERIOSCLEROSIS VEGENICS PTY LIMITED (AU) 2018-05-03 — — US disclosed
US-9896499-B2 Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis VEGENICS PTY LIMITED (AU) 2018-02-20 — — US disclosed
US-9469641-B2 Pyrido[3,4-B]indoles and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2016-10-18 — — US disclosed
US-9260429-B2 Pyrido[3,4-B]indoles and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2016-02-16 — — US disclosed
US-20150218249-A1 GROWTH FACTOR ANTAGONISTS FOR ORGAN TRANSPLANT ALLOIMMUNITY AND ARTERIOSCLEROSIS LICENTIA LTD. (FI) 2015-08-06 — — US disclosed
US-9073997-B2 Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis VEGENICS PTY LIMITED (AU) 2015-07-07 — — US disclosed
US-20130190323-A1 PYRIDO[3,4-B]INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2013-07-25 — — US disclosed
WO-2008101824-A1 IMIDAZO[1',5':1,6] PYRIDO[3,4-B]INDOLES DERIVATIVES AND THERAPEUTICAL USE THEREOF FOURTILLAN (FR) 2008-08-28 — — WO disclosed
WO-2001078781-A9 METHODS FOR PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS UNIV JOHNS HOPKINS (US) 2002-07-25 — — WO disclosed
EP-0859778-B1 TETRAHYDROIMIDAZOPYRIDOINDOLEDIONES AS INHIBITORS OF cGMP SPECIFIC PDE ICOS CORP (US) 2001-12-19 — — EP disclosed
US-6218400-B1 TREATING ANGINA, HYPERTENSION, PULMONARY DISEASE, VASCULAR DISORDERS, STROKE, BRONCHITIS, ASTHMA, RHINITIS, GLAUCOMA, SEXUAL DISORDERS, AND DISORDERS OF GUT MOTILITY ICOS CORPORATION 2001-04-17 — — US disclosed
US-6143757-A DRUGS FOR CARDIOVASCULAR OR SEXUAL DISORDERS ICOS CORPORATION (US) 2000-11-07 — — US disclosed
US-6001847-A 5,6,11,11A-TETRAHYDRO-1H-IMIDAZO(1'5':1,6)PYRIDO(3,4-B)INDOLE -1,3(2H)-DIONE DERIVATIVES; INHIBITORS OF CGMP SPECIFIC PHOSPHODIESTERASE; CARDIOVASCULAR DISORDERS; ERECTILE DYSFUNCTION ICOS CORPORATION (US) 1999-12-14 — — US disclosed
WO-1999059584-A1 COMBINATION OF PHENTOLAMINE AND CYCLIC GMP PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION SCHERING CORPORATION (US) 1999-11-25 — — WO disclosed
EP-0859778-A2 CHEMICAL COMPOUNDS ICOS CORPORATION (US) 1998-08-26 — — EP disclosed
WO-1996032003-A2 TETRAHYDROIMIDAZOPYRIDOINDOLEDIONES AND THEIR USE AS MEDICAMENTS ICOS CORPORATION (US) 1996-10-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162859-A1 TETRACYCLIC AUTOTAXIN INHIBITORS ENPP2, SERPINB1, UACA MAPT 476/4885LMNA 1534/4885GAA 98/4885
US-20130190323-A1 PYRIDO[3,4-B]INDOLES AND METHODS OF USE HTR3B, HTR4, HTR2C MAPT 214/4885LMNA 4568/4885GAA 3526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.